We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
High demand for genomic sequencing across the biotech industry drove Illumina to record revenues this past quarter, outperforming expectations and boosting the company’s stock price by over 7% in premarket trading.